In the effort to explain gender-related differences of the cardiovascular system, the renin-angiotensin system experienced intensive exploration. Indeed, the development of hypertension as well as the progression of coronary artery disease and heart failure have two factors in common: (1) display distinct gender specific characteristics and (2) are enhanced by the renin-angiotensin system. It is therefore interesting to note that data from experimental animals, epidemiological surveys, and clinical investigations suggest that the components of the circulating as well as tissue-based renin-angiotensin system are markedly affected by gender. However, the issue is complicated by counter-regulatory effects of estrogen on the system with the substrate, on one hand, and the processing enzymes as well as the chief receptor, on the other hand. In fact, angiotensinogen is up-regulated particularly by oral administration of estrogen, whereas renin, angiotensin-converting enzyme (ACE), and AT-1 receptor are down-regulated by the hormone. While under well-defined experimental conditions the net effect of estrogen appears to result in suppression of the renin-angiotensin system, the clinical situation may be more complex. The judgment is further complicated by the difficulty in precisely measuring the activity of the system at the tissue level. Moreover, clinically relevant read-outs for the activity of the renin-angiotensin system may be regulated multifactorially or only indirectly affected by the system. Nevertheless, the undisputable, profound biochemical changes in the renin-angiotensin system related to the estrogen status allow speculation that such interaction explains some of the differences in the cardiovascular system of men and women.
Regulation of RAS components by estrogen
tion of the roles of ACE and the AT-1 receptor allow to judge the situation differently. Indeed, experimental aniGender and sex hormones affect the components of the mals with a stimulated renin-angiotensin system and renin-angiotensin system (RAS) by a number of mechahypertension may experience a significant inhibition of nisms ( Fig. 1) . Unfortunately, counter-regulatory actions angiotensin II generation and blood pressure reduction as well as some difficulties in studying components of the with estrogen replacement [8] [9] [10] [11] [12] [13] [14] [15] . In humans, the net renin-angiotensin system biochemically or functionally at effect of physiological estrogen concentrations on the the tissue level have blured our knowledge. In fact, it was overall activity of the system and, as a consequence, blood only 15 years ago that the consensus in the scientific pressure appears to be similar. However, the data vary to community favoured the notion that estrogen activates the some extent and have to be evaluated on an individual renin-angiotensin system [1] [2] [3] [4] [5] [6] [7] . Nowadays, more precise basis. In fact, a recent meta-analysis suggested overall a measurements of plasma renin as well as a better appreciamild increase in blood pressure of women using contraceptive medications and a mild decrease in those using estrogen replacement therapy [16] . 
1.1.
Angiotensinogen stimulation of angiotensinogen production [19, 20, 22] . Thus, pharmacological rather than physiological concenAngiotensinogen or renin substrate is predominantly trations of estrogen account for much of the angiotensynthesized in the liver. An estrogen response element in sinogen stimulation (and LDL lowering), and can, thereits gene promoter markedly stimulates angiotensinogen fore be prevented by transdermal or intramuscular estrogen synthesis and explains higher circulating levels in women replacement [19, 20, [22] [23] [24] . as compared to men [17, 18] . Moreover, premenopausal women have slightly higher angiotensinogen levels than 1.2. Renin postmenopausal women and estrogen replacement therapy or contraceptive medication both increase angiotensinogen For decades, studies on renin relied on measurement of in the circulation [5, 19, 20] . Interestingly, high concenplasma renin activity. In this assay the cumulative genetrations of estrogen in the portal vein, i.e. the liver's ration of angiotensin I rather than renin itself is being exposure to unphysiological concentrations after oral adquantified (Fig. 2) . Measurements of plasma renin activity ministration of estrogen, cause most of the well-docuare partially dependent on the concentration of angiotenmented angiotensinogen stimulation [21] . In fact, studies sinogen (or renin substrate) in the assay system. Indeed, employing transdermal estrogen replacement therapy that plasma renin activity is, in part, reflecting renin substrate avoided the first pass effect demonstrated only mild if any levels which, as outlined above, are markedly higher in women using contraceptives or oral estrogen replacement 1.5. Other components medication. It is not surprising therefore that plasma renin activity, i.e. angiotensin I levels measured in the assay, are
Further interaction between estrogen status and the increased or rather variable in women using oral estrogen renin-angiotensin system may be related to plasma levels replacement [1, 2, 25] . This ex vivo interaction can be of the vasodilatory heptapeptide ANG1-7 [13, 36, 37] , neutralized by either addition of excess amounts of ankininogene [38] , renin binding protein [39] , and the AT-1 giotensinogen (the assay is then named plasma renin receptor [40, 41] . However at present time, only scattered concentration) or, nowadays, by direct immunometric data are available to illustrate such potential effects. measurements of renin. In other words, these modifications Moreover, the central role of the renin-angiotensin of the assay allow to measure renin rather than a combined system within the neurohormonal network raises the option effect of angiotensinogen and renin.
for indirect modulation of its components. For example, The investigations on the interaction between the esthe estradiol metabolites 2-hydroxyestradiol and 2-methoxtrogen status and renin largely reflect these technological yestradiol inhibit endothelin-1 synthesis by means of an aspects. While traditionally the overall consensus sugestrogen receptor-independent mechanism [42] . Lower gested that renin activity is stimulated by estrogen, current endothelin levels on the other hand may lead to lower RAS studies using direct assays document that the enzyme activity [43] . Likewise, estrogen levels have profound levels are actually suppressed [6, 7, 19, [26] [27] [28] . Indeed, implications for NO synthesis which, in turn, is known to some studies that used both technological approaches play a central role in regulation of renin synthesis report opposite responses of plasma renin activity and [7, 44, 45] . concentration in individual patients receiving estrogen replacement therapy ( Fig. 2) [24]. Direct measurements of 1.6. RAS and testosterone renin by the radioimmunometric assay clearly document lower levels in women as compared to men [19] . MoreIn addition to the effects of estrogen, gender-related over, premenopausal women and postmenopausal women differences of the renin-angiotensin system may be amusing estrogen replacement therapy display lower renin plified by testosterone. Testosterone treatment in ovarieclevels as compared to men or postmenopausal women tomized female rats increases plasma renin activity [46] . without substitution [19, 29] . The precise mechanism of On the other hand, plasma renin activity decreases with renin down-regulation by estrogen is not entirely clear. A castration in male rats [46] . Furthermore, it was found that molecular interaction may be mediated by modulation of there is a linear correlation between the level of testosympathetic activity which is known to be lowered by sterone and plasma renin activity in castrated rats treated estrogen replacement therapy [30] . Suppression of the with increasing doses of testosterone. Moreover, molecular sympathetic nervous system, on the other hand, is known studies have shown that angiotensinogen mRNA is higher to suppress the renin production at the macula densa for in male rats than in female and that castration reduces example via a CREB element in the renin promotor whereas testosterone treatment increases angiotensinogen [31, 32] , and other mechanisms [33] .
mRNA [26, 46] . An increase in angiotensinogen substrate may in part explain the increase in renin activity men-1.3. Angiotensin-converting enzyme tioned above.
The implications of estrogen status for plasma and tissue ACE activity were only recently explored. In fact, both the 2. Estrogen-mediated modulation of the RAS in conversion rate of angiotensin I to angiotensin II as well as pathophysiological conditions the biochemical activity of the enzyme appear to be affected by estrogens in experimental animals [6, 13, 34] . In
The implications of the estrogen status in modulating the addition, the majority of human studies documents a mild renin-angiotensin system may differ (1) depending on the to moderate suppression of ACE activity with estrogen mode of estrogen administration and (2) on the experimenreplacement therapy [19, 27] .
tal or clinical context. Most notably, physiological levels of estrogen or those achieved with estrogen replacement 1.4. AT-1 receptor therapy are largely different from the effects seen with synthetic preparations or high doses used for contraceptive Most of the traditionally observed effects of the reninutilization of the hormone. Moreover, equine and human angiotensin system are mediated by the AT-1 receptor.
estrogen metabolites or different dosages may differ in Like renin and ACE, the AT-1 receptor appears to be down their effects. Perhaps even more importantly, the route of regulated by estrogen replacement therapy [12, 35] . Both, application, i.e. transdermal vs. oral, may affect the studies in humans as well as experimental animals obintegrated activity of the system. served consistently such interaction at the level of receptor In addition, disease conditions that are largely dependent density as well as down-stream activation steps [12, 35, 36] .
on the activated renin-angiotensin system may visualize estrogen effects more prominently. For example, transdocument that angiotensin II increases peak plasma aldosgenic rats with renin-related hypertension display a terone levels in dependence of the estrogen status with profound sexual dimorphism in blood pressure regulation, highest levels observed in male or ovariectomised rats that is largely dependent on the interaction between [12] . estrogen and components of the renin-angiotensin system Finally, Nickenig et al. [48] demonstrated that the [13, 47] . Likewise, in two-kidney-one-clip rats (2K1C) generation of free radicals by vascular smooth muscle cells plasma renin activity appears to increase less in female as can be enhanced by angiotensin II but largely suppressed compared to male rats [9] . Ovariectomy, on the other hand, by estrogen. In fact, these data offer a potential mechanism can enhance the rise of renin in 2K1C rats [9] . Consethat explains the shift of complications from atherosquently, renal hypertension develops more frequently in clerotic disease into the postmenopausal age-group [48, 60] . male or ovariectomized rats as compared to female 2K1C animals.
Hypercholesterolemia and estrogen deficit may also 4. Modification of genotype-phenotype interaction by affect the level of AT-1 receptor expression. Indeed, both estrogen conditions up-regulate synergestically, AT-1-mRNA levels in vascular smooth muscle cells and, thus, may amplify the In addition to numerous exogenous factors, genotypic risks of menopause for the cardiovascular system variation determines the activity of the renin-angiotensin [35, 48, 49] .
system. In this respect, numerous studies demonstrated that Estrogen may also affect vascular tone and the activity genetic polymorphisms of the ACE, angiotensinogen, or of the RAS by indirect mechanisms. For example, estrogen AT-1 receptor genes display more profound effects in men reverses acetylcholine-induced vasoconstriction via posthan in women [61] [62] [63] [64] [65] [66] . Indeed, most of such association sible facilitation of endothelium-dependent relaxation studies were only positive when the subgroup of men was [50, 51] . This may be mediated by an enhancement of NO considered. Likewise, the correlations of plasma ACE production via stimulation of NO-synthase [52] [53] [54] , meactivity with blood pressure or left ventricular hypertrophy diated in part by an estrogen a-receptor-dependent action were predominantly observed in men [63,67]. [55] .
A rather distinct phenotype related to the renin-angiotensin system is non-modulation essential hypertension [61] . Herewith, abnormal responses of renal blood flow or 3. Modulation of angiotensin II effects by estrogen aldosterone secretion to angiotensin II on high or low salt diet are characterized. Interestingly, in women, the expresIn addition to the bidirectional regulation of plasma and sion of the non-modulation phenotype is observed less tissue components, estrogen may affect the down-stream frequently than in men and almost absent in the presignaling of the AT-1 receptor [35] . In this respect, menopausal state [61] . Taken together, the modulatory role experimental studies demonstrated that estrogen may shift of the estrogen status with respect to the renin-angiotensin the vasoconstrictor-vasodilator balance of the renin-ansystem may relate to the genetically determined activity of giotensin system [9, 13, 56] . For example, transgenic anithe system in a given individual. mals with high renin hypertension displayed an attenuated pressure response to intravenous angiotensin after estrogen replacement [13] . Interestingly, angiotensin II actions in 5. Clinical outlook the central nervous system may also largely differ by gender. For example, the pressure and dipsogenic response
The progression of renal or cardiac failure as well as the to centrally administrated angiotensin II in anesthetized rate of cardiovascular mortality differ largely in predogs was substantially augmented in male animals [57] . menopausal women as compared to men of the same age Similarly, studies in healthy humans suggest that the group. Even more dramatic is the difference in prevalence half time of the pressure response after discontinuation of of atherosclerotic disease between men and women. The angiotensin may be greater in men than in women [58] . A mechanisms explaining the protective effects of female vascular bed that is particularly sensitive to angiotensin II gender for the heart, vessels and kidneys are incompletely is the renal circulation. In response to angiotensin II both understood. Interestingly, recent evidence suggests that the men and women display a reduction in effective renal estrogen-related organ protection may be more profound in plasma flow [58, 59] . However, under this condition, only the setting of primary prevention, as a large, prospective men maintain their glomerular filtration rate (GFR) sugtrial in the setting of secondary prevention has failed to gesting a significant augmentation of filtration fraction document such benefit (HERS, [68] ). The distinction [59] . In addition, angiotensin-related aldosterone secretion between primary and secondary prevention may not apply appears to be effected by the estrogen status. While some to the renin-angiotensin system since its inhibition is but not all studies observed lower aldosterone concenunequivocally beneficial for patients with or without trations in women, experimental studies in rats clearly vascular, cardiac or renal disease. better defined response of the renin-angiotensin system.
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